PharmEng International Inc.

PharmEng International Inc.

December 11, 2008 11:13 ET

PharmEng Announces Organizational Restructuring

TORONTO, ONTARIO--(Marketwire - Dec. 11, 2008) - PharmEng International Inc. (TSX VENTURE:PII), a full-service consulting and contract manufacturing company, today announced, as a result of a corporate realignment, that David Leonard, President, Keata Sydney has left the organization to pursue other interests. "On behalf of the Company, I would like to thank David for his service and leadership at Keata, during which time Keata designed, constructed and successfully commissioned the pharmaceutical manufacturing facility in Sydney. This realignment reflects our continued efforts to streamline our contract manufacturing operations while we complete our strategic assessment of the Sydney facility. We wish David well in his future endeavors," stated Alan Kwong, CEO of PharmEng International Inc.

Alex Della Mora has been appointed interim General Manager of the Keata Sydney facility along with Jack Basarke being responsible for the Company's overall continued quality assurance and regulatory affairs. Alex has many years of contract manufacturing experience having been the Perth Site Director and was integral in the relocation of the Perth manufacturing operations to the Sydney facility last year. Jack has over 35 years experience working in the pharmaceutical industry with his former position before joining PharmEng as Head of the Drug GMP Unit for the Ontario Region of Health Canada.

About PharmEng International Inc.

PharmEng International Inc., headquartered in Toronto, Canada, is a full-service consulting and contract manufacturing company that serves the pharmaceutical and biotechnology industries in North America and internationally. Consulting services include project management, engineering, GMP, validation, calibration, regulatory compliance and certified training. Contract manufacturing includes pharmaceutical support, formulation development, laboratory testing, and finished solid dosage and liquid products. PharmEng's shares trade on the TSX Venture Exchange under the symbol PII. To find our more about PharmEng International Inc. (TSX-V: PII), visit our website at


Certain statements in this press release may include "forward-looking" statements which involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements of PharmEng to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. When used in this press release, such statements use such words as "may", "will", "expect", "anticipate", "project", "believe", "plan", and other similar terminology. The risks and uncertainties are detailed from time to time in reports filed by PharmEng with the securities regulatory authorities in all of the provinces and territories of Canada. New risk factors may arise from time to time and it is not possible for management to predict all of those risk factors or the extent to which any factor or combination of factors may cause actual results, performance and achievements of PharmEng to be materially different from those contained in forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results.

Contact Information

  • PharmEng International Inc.
    Charles Ivey
    Vice President
    (905) 415-3922 x 116